Jon Tumen, MD
Pulmonary Disease · Nashville, TNNPI 1831139799
Payments from drug & device makers
Across 837 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$2K
- GSK$2K
- Insmed, Inc.$1K
- Grifols USA, LLC$910
- plus $6K from 30 others
What the payments were for
- Food & beverage$15,89899%
- Education$1691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 123 | $2,610 |
| AstraZeneca | 108 | $2,224 |
| Actelion Pharmaceuticals US, Inc. | 105 | $1,881 |
| GSK | 128 | $1,668 |
| Insmed, Inc. | 49 | $1,118 |
| Grifols USA, LLC | 42 | $910 |
| Sanofi | 29 | $701 |
| Mylan Specialty L.p. | 33 | $593 |
| United Therapeutics Corporation | 27 | $579 |
| Electromed, Inc. | 32 | $560 |
| Regeneron Healthcare Solutions, Inc. | 28 | $558 |
| Pfizer | 24 | $367 |
| Merck | 15 | $336 |
| Amgen | 14 | $262 |
| Inspire Medical Systems, Inc. | 3 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $196 |
| Axsome Therapeutics, Inc. | 7 | $169 |
| Genentech USA, Inc. | 9 | $156 |
| Johnson & Johnson | 10 | $138 |
| Inari Medical, Inc. | 3 | $133 |
| Jazz Pharmaceuticals Inc. | 4 | $82 |
| Bayer | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 7 | $73 |
| Mallinckrodt Enterprises LLC | 3 | $69 |
| Vifor Pharma, Inc. | 3 | $69 |
| Novartis | 4 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Pulmonx Corporation | 2 | $40 |
| Circassia Inc. | 2 | $33 |
| Boston Scientific | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
| Philips North America LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$530
- SYMBICORT$400
- BREZTRI$297
- BEVESPI AEROSPHERE$233
- TEZSPIRE$166
- AIRSUPRA$166
- Inspire Upper Airway Stimulation System$124
- BREZTRI AEROSPHERE$123
How this compares
$16,066 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 175 | $136,574 |
| Dupixent PenDupilumab | 30 | $103,926 |
| TezspireTezepelumab-Ekko | 25 | $103,210 |
| OfevNintedanib Esylate | 12 | $80,007 |
| Breo ElliptaFluticasone/Vilanterol | 116 | $67,909 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $53,910 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $23,516 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $21,787 |
| EliquisApixaban | 25 | $19,362 |
| Spiriva HandihalerTiotropium Bromide | 26 | $19,309 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $18,983 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $15,699 |
| Tiotropium Bromide | 13 | $13,080 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $11,565 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $9,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,668 | $243,698369 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,224 | $164,928123 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $2,610 | $122,54981 claims |
| PfizerEliquis | $367 | $19,36225 claims |
| Johnson & JohnsonXarelto | $138 | $6,28612 claims |
| MerckDulera | $336 | $3,78311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Fabien MaldonadoNashville$2.5M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Otis RickmanNashville$426K
- Jonathan KropskiNashville$419K
- Justin HewlettNashville$388K
- Susan GarwoodNashville$351K
- Margaret SalisburyNashville$345K
- Joao DeandradeNashville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.